MEDICA 2019
in any test, it is indicated by an amber alert, advising them to seek medical help; if there is no blood present, the reader returns a green tick. However, while Measure is said to offer fast and accurate results, some factors can cause a false positive or false negative result. Users are therefore advised to follow certain dietary guidelines, such as avoiding red meat (it contains haemoglobin, which can trigger the test to cause a false positive result) as well as certain medicines that can interfere with the result of the test by causing gastrointestinal irritation and bleeding, causing a false positive result. “Measure Bowel Health comes as
a reader,” Dr. Bianchi noted, “which controls the test timing and displays the results using coloured LEDs, and a cartridge/sampler which contains all reagents. The user takes a sample of stool with the sampler, and inserts it into the cartridge, which then seals to eliminate any risk of leakage. This initiates the test. After 3 tests, the reader will display a result, either green (negative) or amber (if any number of tests return positive).
“While no cancer screening test is
perfect, Measure Bowel Health has a sensitivity of 97.4% and a specificity of 87.2%, comparable to that of the NHS Screening Standard.”
Extolling the benefits for clinicians,
Dr. Bianchi commented: “From a clinical point of view, the advantage is that an easy-to-use technology and IVD would increase compliance with FOB screening. Furthermore, the digital nature of the device allows us to programme the detection threshold through the software of the reader to satisfy the needs of individual clinicians or diagnostic centres. This is very important clinically, as other FOB tests have detection thresholds which are hardware-set and cannot be changed easily. “In the UK, for example, NICE recommends FOB testing (NICE Diagnostic Guideline 30) to use a threshold of 10 ug/g (blood/stool), but the NHS screening programme has detection thresholds set regionally (150ug/g in Wales, 120ug/g in England and 60ug/g in Scotland). Having a digital device where the threshold can be set through software has an advantage as the test can be tailored both for the location and for the condition (for example, after colon cancer surgery, the threshold can be changed from a screening threshold to a follow-up/management threshold).”
Catering for primary care
MeasurePRO, which will be launched later this year, is a point-of-care device that operates with the same easy-to-use technology as Measure. The professional testing kit however, designed for the primary care market, comes with changes to the design, including: l A multi-use reader with a rechargeable battery and connectivity
OCTOBER 2019
l A new cartridge design that allows users to take stool samples at home and seal them into the cartridge for transport without initiating the test. The professional user then has an extra piece of kit that allows them to initiate the test in their clinic/GP office.
The new professional version of the Measure self-testing kit will be presented at this year’s Medica, continuing Oxford MEStar’s work in supporting the early diagnosis of bowel cancer – a cancer that causes 16,000 deaths in the UK every year, and where over half of cases are preventable. With cases now increasingly more common in younger people, there is a stronger necessity for early diagnosis, with medical journals such as Current Gastroenterology Reports touting the need to extend screening earlier than currently recommended. Dr Bianchi concluded: “The Measure bowel cancer test is the first in a line of digital testing kits that we are currently
developing in support of early diagnosis and treatment. “We are proud to continue our work with University of Oxford and Glasgow academics to develop new products based on the Measure technology, including clinical and home testing products that can help diagnose and potentially cure other cancers and infectious diseases. “Supporting early diagnosis in bowel cancer is vital. We look forward to launching our professional testing kit at MEDICA as well as expanding our distribution of the self-test product in other EU countries and beyond.” In the UK, one in 18 women and one in 15 men will be diagnosed with bowel cancer in their lifetime. While the symptoms of bowel cancer are often hidden, a person’s chances of surviving are much higher when it’s caught early. To find out more about Measure Bowel Health visit Oxford MEStar on the ABHI UK Pavilion Hall 16.
CSJ
VIO®
3
Electrosur with maxim
g p Erb
gery mum convenience
Handling of the VIO 3 with stepGUIDE, the new modes,
Then there are the other advantages:
be Medical UK Ltd Leeds United d Kingdom +44 113 253 0333
erbe-uk.com
WWW.CLINICALSERVICESJOURNAL.COM I
63
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
